cas 4720-29-0|| where to buy N-Benzyl-3-aminopropan-1-ol

Nombre del producto:N-Benzyl-3-aminopropan-1-ol

IUPAC Name:3-(benzylamino)propan-1-ol

Unidad de embalaje	Stock disponible	Precio($)
CM343598-25g	in stock	Ǚľ
CM343598-100g	in stock	ŌƈǸ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 4720-29-0 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :4720-29-0; Fórmula molecular:C10H15NO; Punto de fusión:-; Código de sonrisas:OCCCNCC1=CC=CC=C1; Densidad:

: Número de catálogo:CM343598; Peso molecular:165.24; Punto de ebullición:; Nº Mdl:MFCD00020622; Almacenamiento:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Brensocatib; May 28 2024, Insmed announced positive topline results from landmark ASPEN study of Brensocatib in patients with bronchiectasis.
Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed for the treatment of patients with bronchiectasis, CRSsNP, and other neutrophil-mediated diseases. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Brensocatib is an investigational drug product that has not been approved for any indication in any jurisdiction.